VANI
Vivani Medical, Inc.
$1.18
-7.81%
$101.8M
No data for this timeframe.
Vol
Market Cap$101.8M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders6 funds
Inst. Value$2.1M
Inst. Activity1 buys / 0 sells
Insider Activity4B / 0S
Insider Net $$7.0M
Reddit Sentiment67° Warm
SEC Reports1
Press Releases1
Exchange Nasdaq·Sector Electromedical & Electrotherapeutic Apparatus·Inc. DE·CIK 0001266806·Prev Close $1.28
Recent Activity
Jun 4, 2026
SEC
Vivani Medical filed an 8-K announcing its presentation at the Jefferies Global Healthcare Conference on June 4, 2026, w
8-K — Impact 3/10
May 18, 2026
earnings_calendar
VANI Q1 2026 Earnings Scheduled — 2026-05-18
May 15, 2026
Insider
Williams Gregg bought 1,587,301 shares
Director @ $1.26 ($2.0M)
Apr 15, 2026
Insider
Williams Gregg bought 1,587,301 shares
Director @ $1.26 ($2.0M)
Mar 15, 2026
Insider
Williams Gregg bought 1,310,680 shares
Director @ $1.03 ($1.4M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
97,985 shares ($120.5K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — NEW
44,858 shares ($63.3K)
Mar 26, 2026
Press
Vivani Medical reported its 2025 financial results, showing increased net losses and declining cash, but highlighted sig
Impact 6/10
Price Targets
$4.83
+309.6% upside
Strong Buy
Current $1.18
Low $3.50
Median $4.00
High $7.00
3 analysts
$3.50
$7.00
Analyst Ratings
2Strong Buy
6Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Sep 2, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| May 19, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 16, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 4, 2025 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $-0.09 ▼ -12.5% | $-0.09 — $-0.09 | 18% YoY | 1 |
| Next FY | $-0.40 ▼ -5.3% | $-0.40 — $-0.40 | -11% YoY | 1 |
| Current FY | $-0.35 | $-0.35 — $-0.35 | 19% YoY | 1 |
| Current Q | $-0.09 ▼ -12.5% | $-0.09 — $-0.09 | 25% YoY | 1 |
Latest Reports
NEUTRAL
8-K
3/10
Vivani Medical filed an 8-K announcing its presentation at the Jefferies Global Healthcare Conference on June 4, 2026, w
Jun 4, 2026
MIXED
Press
6/10
Vivani Medical reported its 2025 financial results, showing increased net losses and declining cash, but highlighted sig
Mar 26, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $1.9M | ADD |
| RENAISSANCE TECHNOLOGIES LLC | $120.5K | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $36.9K | NEW |
| MORGAN STANLEY | $419.00 | TRIM |
| BANK OF AMERICA CORP | $48.00 | NEAR_EXIT |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 15, 2026 | Williams Gregg | BUY | $2.0M |
| Apr 15, 2026 | Williams Gregg | BUY | $2.0M |
| Mar 15, 2026 | Williams Gregg | BUY | $1.4M |
| Feb 15, 2026 | Williams Gregg | BUY | $1.6M |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
6 institutional holders with $2.1M total value (1,681,191 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, CHARLES. Net buying activity: 1 institutions added/increased vs 0 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 1,552,809 | $1.9M | 92.4% | ADD +48.1% |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 97,985 | $120.5K | 5.8% | DOUBLED +118.4% |
| 3 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 30,016 | $36.9K | 1.8% | NEW |
| 4 | MORGAN STANLEY | 341 | $419.00 | 0.0% | TRIM -26.1% |
| 5 | BANK OF AMERICA CORP /DE/ | 39 | $48.00 | 0.0% | NEAR_EXIT -86.6% |
| 6 | WELLS FARGO & COMPANY/MN | 1 | $1.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 44,858 | 97,985 | +118.4% | $120.5K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | NEW | — | 44,858 | — | $63.3K | 2025-Q3 |
| UBS Group AG | TRIM | 11,868 | 7,508 | -36.7% | $10.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 321 | 43 | -86.6% | $61.00 | 2025-Q3 |
| VANGUARD GROUP INC | ADD | 967,398 | 1,432,586 | +48.1% | $1.8M | 2025-Q2 |
| UBS Group AG | ADD | 7,946 | 11,868 | +49.4% | $15.3K | 2025-Q2 |
| UBS Group AG | TRIM | 18,818 | 7,946 | -57.8% | $8.3K | 2025-Q1 |
| CITADEL ADVISORS LLC | EXIT | 33,922 | 0 | -100.0% | $0.00 | 2025-Q1 |
| CITADEL ADVISORS LLC | ADD | 25,208 | 33,922 | +34.6% | $39.3K | 2024-Q4 |
| UBS Group AG | DOUBLED | 5 | 18,818 | +376260.0% | $21.8K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 30,016 | — | $35.1K | 2024-Q3 |
| MORGAN STANLEY | TRIM | 566 | 418 | -26.1% | $489.00 | 2024-Q3 |
1 unique insiders with 4 transactions. Net insider value: $7.0M ($7.0M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 15, 2026 | Williams Gregg | Director | BUY | 1,587,301 | $1.26 | $2.0M |
| Apr 15, 2026 | Williams Gregg | Director | BUY | 1,587,301 | $1.26 | $2.0M |
| Mar 15, 2026 | Williams Gregg | Director | BUY | 1,310,680 | $1.03 | $1.4M |
| Feb 15, 2026 | Williams Gregg | Director | BUY | 1,601,941 | $1.03 | $1.6M |
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 0 mixed, 1 neutral. Avg impact: 3.0/10.
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 2 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$4.83 mean target
+309.6% upside
Strong Buy (3.00)
$3.50 Low
$7.00 High
| Metric | Value |
|---|---|
| Current Price | $1.18 |
| Target Low | $3.50 |
| Target Mean | $4.83 |
| Target Median | $4.00 |
| Target High | $7.00 |
| # Analysts | 3 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-09-30 |
$-0.09 | $-0.09 | $-0.09 | 18.2% | -12.5% | — | $0.0B | 0.0% | 1 |
| Next FY 2027-12-31 |
$-0.40 | $-0.40 | $-0.40 | -11.1% | -5.3% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.35 | $-0.35 | $-0.35 | 18.6% | — | — | $0.0B | 0.0% | 1 |
| Current Q 2026-06-30 |
$-0.09 | $-0.09 | $-0.09 | 25.0% | -12.5% | 0↑ 1↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.090 | |
| 7d ago | $-0.080 | -0.010 |
| 30d ago | $-0.080 | -0.010 |
| 60d ago | $-0.090 | |
| 90d ago | $-0.090 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 31, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Sep 2, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 19, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 16, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 4, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 26, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 13, 2025 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Nov 7, 2024 | HC Wainwright & Co. | INITIATE | — | Buy |
| Dec 5, 2022 | ThinkEquity | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% | |
| Jan 1, 2026 | 2 | 6 | 1 | 0 | 0 | 89% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 20, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 18, 2026
earnings_calendar
VANI Q1 2026 Earnings Scheduled — 2026-05-18
May 13, 2026
earnings
Vivani Medical Reports First Quarter 2026 Financial Results and Provides Business Update
<p align="center"><strong><em>Initiation of SLIM-1™ clinical trial, a Phase 1 study of NPM-139, a semaglutide implant under development for chronic we
May 11, 2026
earnings_calendar
VANI Q1 2026 Earnings Scheduled — 2026-05-11
Apr 20, 2026
short_volume
Short Volume: VANI — 60.6% short (0.3M / 0.6M)
Short: 338,645 | Exempt: 7,580 | TRF Vol: 558,758 | Short Ratio: 60.6% | Off-exchange volume (dark pool + OTC)
Mar 26, 2026
earnings
Vivani Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
<p align="center"><em>Successful completion of first-in-human study LIBERATE-1 paired with preclinical proof of concept data for a semaglutide implant
Mar 26, 2026
earnings_calendar
VANI Q4 2025 Earnings Scheduled — 2026-03-26